This Week in GLP-1s / Week 14, 2026
FDA approves Foundayo, Eli Lilly's new oral GLP-1 pill for obesity
Lead item
FDA approves Foundayo, Eli Lilly's new oral GLP-1 pill for obesity
The FDA has approved Foundayo, a new oral pill for obesity developed by Eli Lilly. The approval makes Foundayo only the second GLP-1 medication cleared for obesity treatment in pill form, joining the oral version of Wegovy already on the market.
The practical significance is real: most GLP-1 medications that have shown meaningful weight loss results are injected, which is a barrier for some patients. An approved oral option expands the range of choices available to people and their doctors, though it does not mean the pill will work the same way, or produce the same results, as injectable versions. Published results show trial participants losing 7.5% to 12.4% of their body weight, with similar GI side effects present as patients taking injectable GLP-1s.
Readers interested in whether Foundayo might be appropriate for them should watch for more detailed clinical data as it becomes public, and discuss any questions about treatment options with their own healthcare provider. Pricing and insurance coverage, which have been major access hurdles for other GLP-1 medications, will also be worth tracking as the drug moves toward pharmacy availability.
Trump Rx Platform & Drug Access
New GLP-1 pill added to Trump Rx platform
CBS News reports that Foundayo, a newly FDA-approved oral GLP-1 weight loss pill, will be listed on the Trump administration's "Trump Rx" cost comparison website. The platform will offer coupons starting at $149 for a first dose to uninsured Americans, though a White House official acknowledged pricing matches the drugmaker's own site. The administration positions Trump Rx as a one-stop shop for comparing GLP-1 medications, though independent verification of any cost savings has not been reported.
What this means for patients
Uninsured patients will soon be able to find coupons for this new needle-free weight loss pill through a government price-comparison website, though it does not appear to offer lower prices than buying directly from the drugmaker.
Oral GLP-1 Launch & Competitive Dynamics
Novo challenges Lilly's oral GLP-1 with rival analysis
Novo Nordisk released an analysis claiming its oral GLP-1 drug outperforms Eli Lilly's newly approved obesity pill Foundayo. Endpoints News reports that only a head-to-head clinical trial could definitively settle the debate between the two companies. Both analyses are industry-sponsored and should be interpreted with that context in mind.
Lilly holds 60% of U.S. incretin market, analysis finds
Eli Lilly has captured approximately 60% of the U.S. incretin market as of early 2026, according to a market analysis in The Chronicle-Journal. The report attributes this lead largely to Lilly's manufacturing capacity and the slightly higher weight loss seen with tirzepatide compared to semaglutide. The publication notes that supply chain disruptions at Lilly's new facilities could open the door for competitors like Amgen and Roche.